Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes.

ABSTRACT: Visual impairment due to glaucoma currently impacts 70 million people worldwide. While disease progression can be slowed or stopped with effective lowering of intraocular pressure, current medical treatments are often inadequate. Fortunately, three new classes of therapeutics that target the diseased conventional outflow tissue responsible for ocular hypertension are in the final stages of human testing. The rho kinase inhibitors have proven particularly efficacious and additive to current therapies. Unfortunately, non-contact technology that monitors the health of outflow tissue and its response to conventional outflow therapy is not available clinically. Using optical coherence tomographic (OCT) imaging and novel segmentation software, we present the first demonstration of drug effects o

SUBMITTER: Li G 

PROVIDER: S-EPMC5014700 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature